Spearhead Capital Advisors’s bluebird bio BLUE Stock Holding History

Spearhead Capital Advisors’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-730	Closed	-$146K	–	200
2021 Q4	$146K	Sell	730 -287	-28%	-$67.7K	0.02%	173
2021 Q3	$252K	Buy	1,017 +74	+8%	+$21.2K	0.03%	173
2021 Q2	$391K	Buy	943 +119	+14%	+$47.1K	0.05%	148
2021 Q1	$322K	Buy	+824	New	+$406K	0.05%	149

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Spearhead Capital Advisors's BLUE Position: Q1 2022 in Review

Spearhead Capital Advisors sold out of bluebird bio (BLUE) in Q1 2022, closing a stake of 730 shares — an estimated $146K sold.

Spearhead Capital Advisors first reported a position in BLUE in Q1 2021 and held it in 4 quarters. The position peaked at $391K in Q2 2021. 174 funds tracked by Wall St. Rank hold BLUE as of Q1 2022.

Spearhead Capital Advisors reported no remaining bluebird bio position as of Q1 2022 after selling out during the quarter.
Spearhead Capital Advisors sold 730 bluebird bio shares in Q1 2022, an estimated $146K.
Spearhead Capital Advisors first reported a position in bluebird bio in Q1 2021 and held it in 4 quarters.
Spearhead Capital Advisors's bluebird bio position peaked at $391K in Q2 2021.
174 funds tracked by Wall St. Rank held bluebird bio as of Q1 2022.

Based on Spearhead Capital Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.